Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetics and Investigation of Optimal Dose of Invanz (Ertapenem) in Hemodialysis Patients

NCT02159859 is registered in ClinicalTrials.gov with Corewell Health East as lead sponsor.

NCT NCT02159859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02159859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetics and Investigation of Optimal Dose of Invanz (Ertapenem) in Hemodialysis Patients
Lead sponsor
Corewell Health East
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2014
Completion date
April 30, 2016
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease